RBOT Vicarious Surgical Inc. OTC · United States

Vicarious Surgical (RBOT) news

Vicarious Surgical Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker RBOT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Vicarious Surgical news

We have not published a story on Vicarious Surgical yet. When there is news, it will appear here.

Vicarious Surgical annual financials

Line	FY2025	FY2024
Research and development	$33.6 million	$40.2 million
Net income (loss)	-$50.2 million	-$63.2 million
Cash from operations	-$45.1 million	-$50.0 million
Cash and equivalents	$2.6 million	$9.7 million
Short-term investments	$7.2 million	$39.4 million

Latest balance sheet, Dec 31, 2025 (10-K): cash and equivalents $2.6 million, plus short-term investments of $7.2 million, $9.8 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Vicarious Surgical

What is the ticker symbol of Vicarious Surgical?

Vicarious Surgical Inc. trades under the ticker RBOT on OTC.

Where is Vicarious Surgical listed?

Vicarious Surgical Inc. is listed on OTC.

Which country or territory is Vicarious Surgical listed under?

Our directory records Vicarious Surgical Inc. under United States.

Does aibio.space cover Vicarious Surgical?

aibio.space lists Vicarious Surgical Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Vicarious Surgical profitable?

Vicarious Surgical Inc. reported a net loss of $50.2 million for the fiscal year ended Dec 31, 2025, and used $45.1 million of cash in operations, per its annual report to the SEC.

How much does Vicarious Surgical spend on research and development?

$33.6 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Vicarious Surgical have?

$9.8 million in cash and short-term investments at Dec 31, 2025, per its 10-K.

Investor discussion: Vicarious Surgical

Members talk about Vicarious Surgical (RBOT). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Vicarious Surgical, newest first. Each line links the filing it comes from.

Jul 27, 2026Listings
Filed to end its SEC reporting. SEC Form 15-12G. Source
Jul 21, 2026Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,5.02,5.07,8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:RBOT on TradingView.

Listing details

Company: Vicarious Surgical Inc.
Ticker: RBOT
Listing: OTC
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction